(CLEVERHEART) University Interventional Core Laboratories

StartSupporting structures(CLEVERHEART) University In...
Expand

Core Facilities (IDUB):

Core Facility: Interventional Cardiology


CLinical EVidencE-based Research in HEART and Vascular Medicine

(CLEVERHEART) University Interventional Core Laboratories, Gdansk, POLAND


#CleverHeartNetwork – Actionable Understanding for Better Value in Heart and Vascular Medicine


ABOUT US

CLEVERHEART University Interventional Core Laboratories will be a unique center on a European scale conducting research on optimization and development of novel therapies in invasive cardiology, with fields of activity including:

– full range of coronary artery revascularisation using state-of-the-art intravascular imaging techniques,

– percutaneous diagnosis and treatment of structural heart diseases, including heart failure,

– (functional assessment of changes in coronary vessels and microcirculation.

The centre will be established on the basis of the long-term experience of the team working at the 1st Chair and Department of Cardiology of the University Clinical Centre of the Medical University of Gdańsk, a multi-profile clinical hospital that provides comprehensive specialist interdisciplinary care. Additionally, through close collaboration with the newly established Centre for Translational Medicine (CMT), domain-specific theoretical and scientific support, the use of artificial intelligence in the automatic interpretation of intravascular imaging, and the ability to correlate novel interventional strategies and metabolomic methods, a unique centre for individual therapy for patients with cardiovascular disease would be created. A detailed assessment of the anatomy and physiology of the coronary circulation will enable the development of both the optimal strategy of interventional and pharmacological treatment. The University Interventional Core Laboratories will work closely with the newly established the Biostatistics and Bioinformatics Core Facility.

Infrastructure intended for the establishment of the centre, with relatively small additional financial outlays will ensure access to diagnostics and therapy of cardiovascular diseases at the highest world level. The implementation involves adapting the premises (650 sq. m., Operating Theatre Cardiac Surgery/Vascular Surgery/Cardiothoracic Surgery) in order to:

– create a hybrid treatment room allowing the fusion of X-ray and tomographic imaging as well as structural and functional assessment methods,

– upgrade rooms for patients who take part in the trial to ensure the highest quality of perioperative care,

– the creation of a professional base for researchers to carry out scientific work, participate in project meetings, carry out administration, plan and analyse performed treatments.

Infrastructure will also be installed to enable 24-hour hemodynamic monitoring of patients during and after surgery and archiving perioperative data. To enable the training of investigators, a transmission facility from the treatment room will be created. In terms of infrastructure, the Base will be partly supported by the newly established Clinical Research Support Centre (CWBK). CLEVERHEART Interventional Core Laboratories will operate within IDUB (Excellence Initiative – Research University), in the Priority Research Areas (POB 2).

Planned purchase of additional equipment for the hybrid treatment room includes:

– innovative integrated intravascular imaging system that uses optical coherence tomography (OCT) and measurement of fractional flow reserve (FFR) after adenosine administration Optis I,

– CoroFlow integrated functional assessment system for lesions in coronary arteries and coronary microcirculation,

– software capable of assessing stenosis significance based on 3D quantitative coronary angiography images, an HD camera system capable of performing live procedures during scientific and training conferences conducted as part of the activities by CLEVERHEART Interventional Core Laboratories.

Aforementioned equipment will significantly increase the precision of performed procedures through the possibility of integrated analysis of stenosis and functional evaluation of coronary artery disease, assessment of coronary microcirculation and the possibility of high-resolution stent visualization that offers co-registration of X-ray and tomographic images and high-resolution 3D imaging (DynaCT Micro).

Integration of complementary imaging modalities using intravascular ultrasound (IVUS), OCT, FFR measurement and invasive microcirculation assessment will enable in-depth analysis of atherosclerotic plaque morphology, functional significance of epicardial coronary stenosis and small vessel dysfunction, invisible in standard X-ray imaging, the so-called coronary catheterization. OCT is also an established tool for optimizing percutaneous coronary intervention (PCI) and stent implantation.

System for integrated functional assessment of lesions in coronary arteries and coronary microcirculation (Coroventis CoroFlow ™, Sweden) enables FFR or instantaneous wave-free ratio (iFR), index of microcirculatory resistance (IMR), coronary flow reserve (CFR) and resistive reserve ratio (RRR), as well as an assessment of myocardial diastolic function based on relaxation time and end-diastolic pressure. Integration of data obtained from these methods will optimize the diagnosis of cardiovascular diseases, and a significant increase in therapeutic precision will not only enable the identification of patients at high risk of a coronary incident, improving significantly the prognosis.

An additional research goal of the works conducted in collaboration with recognized experts in the field of invasive cardiology is to create algorithms for the automatic detection of lesions in the highest risk coronary vessels in intravascular imaging. The fusion of angiographic and echocardiographic images will enable international research on the diagnosis and treatment of structural heart diseases, enable the creation of algorithms to support decision-making during treatment of structural heart defects using artificial intelligence, enable improvement of risk stratification strategies in patients undergoing percutaneous interventions on the heart valves, such as transcatheter aortic valve implantation (TAVI) or percutaneous mitral valve regurgitation treatment using the MitraClip system.

In terms of research and development, the team, in collaboration with Polimed, is currently participating in creating a permanent implant to connect the atria of the heart to improve symptoms of heart failure, exercise tolerance, reduce dyspnoea, optimize the quality of patients’ life, and thereby reduce the need for hospitalization. The potentially marketed new medical device – a state-of-the-art, flow-modulated atrial implant – is therefore intended for the treatment of patients diagnosed with heart failure, in particular those at an advanced stage of the disease, preventing them from normal functioning.

As far as microcirculation assessment is concerned, projects that use the Coroventis CoroFlow™ system are planned, including multicentre, randomized, double-blind, placebo-controlled trials to prove the superiority of a novel therapeutic strategy for patients with angina pectoris without significant coronary artery disease compared to the current treatment recommended in the guidelines of the European Society of Cardiology. Planned research will be conducted in cooperation with recognized experts in the field of invasive and experimental cardiology, including Prof. Juan Luis Gutierrez-Chico (Spain), Prof. Thomas Luescher (UK), Prof. Christian Templin (Switzerland), Prof. Salvatore Brugaletta (Spain), Prof. Patrick Serruys (UK), Rienk Nieuwland, PhD (The Netherlands), Prof. Jolanta Siller-Matula (Austria), Prof. Tomasz Smoleński (Poland), Prof. Shmuel Banai (Israel), Prof. Amir Lerman (USA), Prof. Richard Heuser (USA), Prof. Dagmara Hering (Poland), Prof. Łukasz Szarpak (Poland).


Centrum_Sercowo-Naczyniowe_Kardiologii_Inwazyjnej.fot.Unsplash.jpg



OUR MISSION

CLEVERHEART Interventional Core Laboratories will become a unique, full-service research and development centre offering an attractive workplace for scientists, presenting itself as a partner for scientific and implementation projects for foreign centres and equipment companies planning to design, patent and evaluate the safety and efficacy of new diagnostic and therapeutic technologies in cardiology.

Relevance to innovation and economic development. Potential of the centre

Cardiovascular diseases account for more than 30% of deaths each year, one third of which occur prematurely, i.e. in people under 70 years of age. Heart failure is the leading cause of repetitive and prolonged hospitalizations in patients over 65 years of age. The results of the planned research aim to develop new and improve and optimize the current interventional cardiology procedures for the treatment of acquired and congenital structural heart diseases, fulfilling one of the main objectives of the National Health Programme, which include the promotion of healthy and active ageing. In 2018, ~100,000 coronary angioplasties, ~1100 TAVI procedures and ~150 percutaneous mitral and tricuspid regurgitation repair procedures using the MitraClip system were performed in Poland. FFR stenosis assessment was performed in ~10,000 patients, IVUS in ~3,600, and OCT in ~380 (source: report of the Association of Cardiovascular Interventions of the Polish Cardiac Society).

Currently, the team of the Invasive Cardiology Laboratory, which is the core of planned CLEVERHEART Interventional Core Laboratories, has experience in both coronary and structural procedures; the center performs approximately 2,000 percutaneous coronary interventions (PCI), 3,500 coronary catheterizations, 100 TAVI procedures, 10 MitraClip implantations, 40 left atrial appendage closures per year. Number of procedures performed in the 1st Cardiology Department of the University Clinical Centre puts the center at the forefront of scientific and research institutions in Poland.

As cardiovascular diseases generate substantial costs due to recurrent symptoms which impair quality of life, require regular inpatient or outpatient care, leading to loss of patients’ professional productivity. The development of new solutions for the diagnosis and comprehensive treatment of these patients will enable a real reduction in premature mortality due to cardiovascular disease, enabling full recovery, improvement in health status and enhancing quality of life of Polish population, which will translate into real savings for the Polish economy, at a relatively low cost.


RESEARCH PROFILE

The planned research infrastructure supported by the experience of the team of the 1st Cardiology Department, the Invasive Cardiology Laboratory and an international panel of experts cooperating with the clinic so far within the framework of scientific projects will make it possible to conduct commercial and non-commercial research programmes of international and domestic companies that create new therapeutic devices.

Scientific and clinical capabilities of CLEVERHEART Interventional Core Laboratories, which include:

1. the infrastructure offered to be used in the project,

2. a team of cardiologists under the supervision of:

  • Dariusz Ciećwierz, Ph.D., the pioneer of invasive cardiology in northern Poland,
  • Prof. Miłosz Jaguszewski, the author of over 180 scientific publications in cardiology (IF 825, iH 25);
  • Prof. Łukasz Szarpak (Warsaw, visiting professor), the expert in emergency and acute cardiology
  • Prof. Marcin Gruchała, Head of the 1st Chair and Department of Cardiology, the expert in heart failure;
  • Prof. Marcin Fijałkowski, the expert in cardiovascular imaging
  • Prof. Tomasz Smoleński, the expert in experimental cardiology
  • Prof. Paul Grundeman (Utrecht, visiting professor), the expert in experimental cardiac surgery,

3. cooperation with CMT, structures of the largest clinical hospital of the University Clinical Centre, Gdańsk University of Technology and equipment companies, will allow us to achieve the intended goal of building a leading research and development centre in Europe, which will simultaneously conduct over a dozen research and implementation projects annually.

Works at CLEVERHEART University Interventional Core Laboratories will be led by the CardioResearch Group team created in 2020 at the 1st Department of Cardiology. The team aims to conduct conceptual work (scientific and implementation projects) and clinical research with a focus on non-commercial clinical trials.




SCIENTIFIC COOPERATION

The team is currently involved in following non-commercial clinical trials:

1. ADONIS-PCI (Prospective, randomized, open-label, non-inferiority trial that evaluates the safety and efficacy of dual anticoagulation therapy with dabigatran and ticagrelor in patients with acute coronary syndrome and non-valvular atrial fibrillation undergoing percutaneous coronary intervention) – Prof. Miłosz Jaguszewski, Natasza Gilis-Malinowska PhD, Tomasz Figatowski, MD. The trial is developed by the team from the 1st Department of Cardiology, University Clinical Centre, funded by a grant from the Medical Research Agency (ABM);

2. ELECTRA SIRO 2 (Evaluation of safety and efficacy of two antiplatelet de-escalation strategies based on ticagrelor in acute coronary syndrome: a randomized, multicentre, double-blind ELECTRA RCT) – Prof. Miłosz Jaguszewski, Agnieszka Mickiewicz Ph.D., Marta Marcinkowska M.D.;

3. EMPATHY [randomized, double-blind, placebo-controlled trial in a population of patients with acute heart failure to compare the prognostic impact of two antidiabetic drugs from the SGLT-2 inhibitor group (dapagliflozin and empagliflozin) and placebo] – Prof. Miłosz Jaguszewski, Joanna Marlęga Ph.D.;

4. HEMOFLOW [Evaluation of the diagnostic accuracy, safety, and cost-effectiveness of the noninvasive iSIL-FFR (in SILico FFR) method to measure the fractional flow reserve in diagnostics of chronic coronary syndromes vs standard diagnostic modalities] – Prof. Miłosz Jaguszewski, Grzegorz Żuk Ph.D., Tomasz Figatowski M.D., Tomasz Michalski M.D.;

5. LEIA-HF (A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy of repeated infusions of levosimendan in out-patients with advanced systolic heart failure) – Prof. Miłosz Jaguszewski, Michał Bohdan Ph.D.;

6. MULTISTARS AMI (Comparison of two treatment strategies: Immediate treatment of the infarct vessel immediately followed by treatment of other significantly narrowed coronary vessels or immediate treatment of the infarct vessel and treatment of other significantly narrowed coronary vessels within the next 3-6 weeks in patients with acute myocardial infarction) – Prof. Miłosz Jaguszewski, who is the Principal Investigator for Poland, Justyna Borowiec M.D., Tomasz Figatowski M.D., Tomasz Michalski M.D.

Planned clinical projects

Apart from the above, a grant application to ABM is being prepared to obtain funding for the LevoTako Study (Effect of levosimendan on adverse events in patients with low left ventricular ejection fraction suffering from Takotsubo syndrome: a randomized, double-blind, placebo-controlled trial) developed by Prof. Miłosz Jaguszewski, Aleksandra Gąsecka Ph.D., Alicja Genc M.D., and Piotr Kasprzyk M.D. (non-commercial clinical trial). The trial will be carried out by scientists from our centre – Radosław Nowak PhD, Iwona Stopczyńska M.D., and Prof. Marcin Fijałkowski.

Conceptual, scientific and implementation work

Our team’s area of interest also includes preclinical research and the search for new medical technologies with the potential to enter routine clinical practice. One such project is led by Prof. Miłosz Jaguszewski, Tomasz Figatowski M.D., and Tomasz Michalski M.D., under the name CLEVERSTENT Project, which involves the creation of a new drug-eluting stent (DES) covered with an additional layer of silver nanoparticles and recombinant tissue plasminogen activator (rt-PA). The main assumption of this concept is to obtain a DES with anti-inflammatory properties within the coronary vessel wall, which in addition to inhibiting the phenomenon of restenosis itself, will enable causal treatment of the process leading to development of atherosclerotic lesions within it. In addition, by topical application of rt-PA, we will achieve a reduction in the duration of antiplatelet therapy. This is particularly beneficial for patients at high risk of bleeding for whom at the present, there is no optimal solution that provides a high safety and efficacy profile for the prevention of recurrent stenosis.

Another project is to develop a new version of the device that provides a permanent atrial communication (VarioFlow) to improve symptoms and prognosis in patients with advanced heart failure.

International network for scientific cooperation

Another important project is the CLEVERHEART Network being developed by Prof. Miłosz Jaguszewski, Prof. Łukasz Szarpak (Warsaw), Aleksandra Gąsecka Ph.D. (Warsaw), Natasza Gilis-Malinowska Ph.D. and Karolina Mosakowska (Co-Founders). The aim of the initiative is to accelerate the exchange of knowledge in the area of cardiovascular diseases between basic and clinical scientists, as well as between individual research centres. This collaboration will ultimately result in a personalized approach to the cardiac patient through the organization of non-commercial clinical trials and conceptual work in the field of cardiovascular diseases.


OUR TEAM

prof._Jaguszewski_fot._Paweł_Sudara_GUMed.jpg

Team Leader

Miłosz Jaguszewski, professor of medical and health science, president of 30 PTK Club, graduate of Medical University of Gdańsk (2007); attended scientific internships at the Department of Cardiology, University Heart Centre based at the University Hospital Zurich and Department of Cardiology, University Hospital Berlin (Benjamin Franklin Campus) (2010-2015); editor-in-chief of Cardiology Journal, author of over 180 scientific publications, IF >800, i-H 20/25 (WoS, Scopus); main clinical and scientific interests: percutaneous intravascular procedures with the use of modern interventional methods, percutaneous recanalization of chronic coronary total occlusions, coronary bioresorbable scaffolds, intravascular imaging (IVUS, OCT), renal artery denervation and Takotsubo cardiomyopathy.






Team members

1. Prof. Miłosz Jaguszewski 2. Natasza Gilis-Malinowska, Ph.D. 3. Dr. Habil. Agnieszka Mickiewicz
4. Radosław Targoński, Ph.D. 5. Dr. Habil. Łukasz Szarpak 6. Aleksandra Gąsecka, Ph.D.
7. Tomasz Figatowski M.D. 8. Tomasz Michalski M.D. 9. Alicja Genc M.D.
10. Witold Bachorski M.D. 11. Jakub Sobolewski M.D. 12. Maksymilian Mielczarek, Ph.D.
13. Dr. Habil. Grzegorz Żuk 14. Damian Świeczkowski, M. Sc. 15. Justyna Borowiec M. A.
16. Jakub Bychowski 17. Piotr Kasprzyk 18. Jarosław Meyer-Szary, Ph.D.
19. Radosław Nowak, Ph.D. 20. Prof. Dagmara Hering 21. Prof. Marcin Hellmann
22. Marta Marcinkowska M.D. 23. Przemysław Ręcki M.D. 24. Joanna Marlęga M.D.
25. Monika Raczkowska-Golanko M.D. 26. Mikołaj Opiełka


Scientific achievements of the CardioResearchGroup

Since its inception in 2020, CardioResearchGroup team members have published extensively in peer-reviewed scientific journals including Q1 journals such as European Heart Journal (IF: 22,673) and Journal of American College of Cardiology (IF: 20.589).


OUR PUBLICATIONS

Year 2021

1. Al-Jeabory M, Gasecka A, Wieczorek W, Mayer-Szary J, Jaguszewski MJ, Szarpak L. Efficacy and safety of tranexamic acid in pediatric trauma patients: Evidence from meta-analysis. Am J Emerg Med. 2021 Feb 8:S0735-6757(21)00115-7. doi: 10.1016/j.ajem.2021.02.009.

2. Borghi C, Domienik-Karłowicz J, Tykarski A, Widecka K, Filipiak KJ, Jaguszewski MJ, Narkiewicz K, Mancia G. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiol J. 2021;28(1):1-14. doi: 10.5603/CJ.a2021.0001.

3. Borkowska MJ, Smereka J, Safiejko K, Nadolny K, Maslanka M, Filipiak KJ, Jaguszewski MJ, Szarpak L. Out-of-hospital cardiac arrest treated by emergency medical service teams during COVID-19 pandemic: A retrospective cohort study. Cardiol J. 2021;28(1):15-22. doi: 10.5603/CJ.a2020.0135.

4. Drozd A, Smereka J, Filipiak KJ, Jaguszewski MJ, Ładny JR, Bielski K, Nadolny K, Ruetzler K, Szarpak Ł. Intraosseous versus intravenous access while wearing personal protective equipment: a meta-analysis in the era of COVID-19.:”https://pubmed.ncbi.nlm.nih.gov/33415967/” Kardiol Pol. 2021 Jan 7. doi: 10.33963/KP.15741

5. Gasecka A, Pruc M, Kukula K, Gilis-Malinowska N, Filipiak KJ, Jaguszewski MJ, Szarpak L. Post-COVID-19 heart syndrome. Cardiol J. 2021 Mar 1. doi: 10.5603/CJ.a2021.0028.

6. Gąsecka A, Pluta K, Solarska K, Rydz B, Eyileten C, Postula M, van der Pol E, Nieuwland R, Budnik M, Kochanowski J, Jaguszewski MJ, Szarpak Ł, Mazurek T, Kapłon-Cieślicka A, Opolski G, Filipiak KJ. Plasma Concentrations of Extracellular Vesicles Are Decreased in Patients with Post-Infarct Cardiac Remodelling. Biology (Basel). 2021 Jan 30;10(2):97. doi: 10.3390/biology10020097.

7. Jaguszewski MJ, Gasecka A, Filipiak KJ, Szarpak L. Levosimendan or dobutamine in patients with low cardiac output syndrome: Results from meta-analysis. Int J Cardiol. 2021 Feb 24:S0167527300359-4. doi: 10.1016/j.ijcard.2021.02.050.

8. Jaguszewski MJ, Szarpak L, Filipiak KJ. Impact of COVID-19 pandemic on out-of-hospital cardiac arrest survival rate. Resuscitation. 2021 Feb;159:40-41. doi: 10.1016/j.resuscitation.2020.12.013.

9. Kato K, Cammann VL, Napp LC, Szawan KA, Micek J, Dreiding S, Levinson RA, Petkova V, Würdinger M, Patrascu A, Sumalinog R, Gili S, Clarenbach CF, Kohler M, Wischnewsky M, Citro R, Vecchione C, Bossone E, Neuhaus M, Franke J, Meder B, Jaguszewski MJ, Noutsias M, Knorr M, Heiner S, D’Ascenzo F, Dichtl W, Burgdorf C, Kherad B, Tschöpe C, Sarcon A, Shinbane J, Rajan L, Michels G, Pfister R, Cuneo A, Jacobshagen C, Karakas M, Koenig W, Pott A, Meyer P, Roffi M, Banning A, Wolfrum M, Cuculi F, Kobza R, Fischer TA, Vasankari T, Airaksinen KEJ, Budnik M, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Chan C, Bridgman P, Beug D, Delmas C, Lairez O, Gilyarova E, Shilova A, Gilyarov M, El-Battrawy I, Akin I, Kozel M, Tousek P, Winchester DE, Galuszka J, Ukena C, Poglajen G, Carrilho-Ferreira P, Hauck C, Paolini C, Bilato C, Sano M, Ishibashi I, Takahara M, Himi T, Kobayashi Y, Prasad A, Rihal CS, Liu K, Schulze PC, Bianco M, Jörg L, Rickli H, Pestana G, Nguyen TH, Böhm M, Maier LS, Pinto FJ, Widimský P, Felix SB, Opolski G, Braun-Dullaeus RC, Rottbauer W, Hasenfuß G, Pieske BM, Schunkert H, Borggrefe M, Thiele H, Bauersachs J, Katus HA, Horowitz JD, Di Mario C, Münzel T, Crea F, Bax JJ, Lüscher TF, Ruschitzka F, Ghadri JR, Templin C. Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. ESC Heart Fail. 2021 Mar 13. doi: 10.1002/ehf2.13165.

10. Kosmalska K, Rzyman M, Miękus P, Gilis-Malinowska N, Nowak R, Fijałkowski M. Usefulness of transesophageal echocardiography before cardioversion in atrial arrhythmias. Cardiol J. 2021;28(1):101-109. doi: 10.5603/CJ.a2019.0056.

11. Kulawiak-Gałąska DA, Gałąska R, Mielczarek M, Drewla P, Jaguszewski MJ, Fijałkowski M, Studniarek M. Pulmonary artery and left atrial appendage anatomical relationship using electrocardiogram-gated computed tomography: An important aspect of left atrial appendage occlusion. Cardiol J. 2021 Feb 26. doi: 10.5603/CJ.a2021.0024.

12. Lewicki L, Fijalkowska M, Karwowski M, Siebert K, Redlarski G, Palkowski A, Targonski R, Siebert J. The non-invasive evaluation of heart function in patients with an acute myocardial infarction: The role of impedance cardiography. Cardiol J. 2021;28(1):77-85. doi: 10.5603/CJ.a2019.0098

13. Ludwin K, Filipiak KJ, Jaguszewski MJ, Pruc M, Paprocki M, Smereka J, Szarpak L, Dabrowski M, Czekajlo M. Place of prefilled syringes in COVID-19 patient based on current evidence. Am J Emerg Med. 2021 Jan;39:234-235. doi: 10.1016/j.ajem.2020.05.016.

14. Melgarejo JD, Thijs L, Wei DM, Bursztyn M, Yang WY, Li Y, Asayama K, Hansen TW, Kikuya M, Ohkubo T, Dolan E, Stolarz-Skrzypek K, Cheng YB, Tikhonoff V, Malyutina S, Casiglia E, Lind L, Sandoya E, Filipovský J, Narkiewicz K, Gilis-Malinowska N, Kawecka-Jaszcz K, Boggia J, Wang JG, Imai Y, Verhamme P, Trenson S, Janssens S, Brien EO, Maestre GE, Gavish B, Staessen JA, Zhang ZY. Relative and Absolute Risk to Guide the Management of Pulse Pressure, an Age-Related Cardiovascular Risk Factor. Am J Hypertens. 2021 Mar 4:hpab048. doi: 10.1093/ajh/hpab048.

15. Melgarejo JD, Yang WY, Thijs L, Li Y, Asayama K, Hansen TW, Wei FF, Kikuya M, Ohkubo T, Dolan E, Stolarz-Skrzypek K, Huang QF, Tikhonoff V, Malyutina S, Casiglia E, Lind L, Sandoya E, Filipovský J, Gilis-Malinowska N, Narkiewicz K, Kawecka-Jaszcz K, Boggia J, Wang JG, Imai Y, Vanassche T, Verhamme P, Janssens S, O’Brien E, Maestre GE, Staessen JA, Zhang ZY; International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcome Investigators. Association of Fatal and Nonfatal Cardiovascular Outcomes With 24-Hour Mean Arterial Pressure. Hypertension. 2021 Jan;77(1):39-48. doi: 10.1161/HYPERTENSIONAHA.120.14929.

16. Merks P, Jakubowska M, Drelich E, Świeczkowski D, Bogusz J, Bilmin K, Sola KF, May A, Majchrowska A, Koziol M, Pawlikowski J, Jaguszewski M, Vaillancourt R. The legal extension of the role of pharmacists in light of the COVID-19 global pandemic. Res Social Adm Pharm. 2021 Jan;17(1):1807-1812. doi: 10.1016/j.sapharm.2020.05.033.

17. Merks P, Świeczkowski D, Balcerzak M, Religioni U, Drelich E, Krysiński J, Hering D, Jaguszewski MJ. Patient counselling service with the use of pictograms as the example of pharmacist intervention to improving compliance and medicine safety. Cardiol J. 2021 Feb 26. doi: 10.5603/CJ.a2021.0022.

18. Mickiewicz A, Marlega J, Kuchta A, Bachorski W, Cwiklinska A, Raczak G, Gruchala M, Fijalkowski M. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland. J Clin Apher. 2021 Jan 2. doi: 10.1002/jca.21872.

19. Ruetzler K, Szarpak Ł, Ładny JR, Gąsecka A, Gilis-Malinowska N, Pruc M, Smereka J, Nowak B, Filipiak KJ, Jaguszewski MJ. D-dimer levels predict COVID-19 severity and mortality. Kardiol Pol. 2021 Feb 25;79(2):232-233. doi: 10.33963/KP.15830.

20. Szarpak L, Filipiak KJ, Gasecka A, Pruc M, Drozd A, Jaguszewski MJ. Correlation between takotsubo cardiomyopathy and SARS-CoV-2 infection. Med Hypotheses. 2021 Jan;146:110454. doi: 10.1016/j.mehy.2020.110454.

21. Szarpak L, Gasecka A, Opiełka M, Gilis-Malinowska N, Filipiak KJ, Jaguszewski MJ. Copeptin level differentiates takotsubo cardiomyopathy from acute myocardial infarction. Biomarkers. 2021 Mar;26(2):75-76. doi: 10.1080/1354750X.2021.1875503.

22. Szarpak Ł, Dzieciątkowski T, Jaguszewski MJ, Ładny JR, Filipiak KJ. Is remdesivir important in clinical practice as a treatment of COVID-19? A study based on meta-analysis data. Pol Arch Intern Med. 2021 Jan 29;131(1):96-97. doi: 10.20452/pamw.15686.

23. Szarpak Ł, Nowak B, Kosior D, Zaczynski A, Filipiak KJ, Jaguszewski MJ. Cytokines as predictors of COVID-19 severity: evidence from a meta-analysis. Pol Arch Intern Med. 2021 Jan 29;131(1):98-99. doi: 10.20452/pamw.15685.

24. Trela M, Szarpak Ł, Filipiak KJ, Meyer-Szary J, Gilis-Malinowska N, Nadolny K, Gąsecka A, Szarpak A, Smereka J, Jaguszewski MJ. Why epinephrine should not always be used in pediatric cardiac arrest? Kardiol Pol. 2021 Feb 25;79(2):235-236. doi: 10.33963/KP.15754.

25. Wilkowski M, Lewicki Ł, Olszewski R, Priebe A, Jaguszewski MJ, Szołkiewicz M. First-inhuman radiofrequency ablation of ventricular tachycardia performed through an Atrial Flow Regulator device. Cardiol J. 2021;28(1):161-162. doi: 10.5603/CJ.a2020.0172. Rok 2020

Year 2020

26. Barycka K, Dzieciątkowski T, Drozd A, Szarpak Ł, Jaguszewski MJ, Filipiak KJ. Should emergency medical service stuff use respirators with filtered valve in COVID-19 pandemic? Adv. Respir. Med. 2020;88(6):638-639.

27. Barycka K, Szarpak L, Filipiak KJ, Jaguszewski MJ, Smereka J, Ladny JR, Turan O. Comparative effectiveness of N95 respirators and surgical/face masks in preventing airborne infections in the era of SARS-CoV2 pandemic: A meta-analysis of randomized trials. PLoS One 2020; 15(12):e0242901.

28. Barycka K, Torlinski T, Filipiak KJ, Jaguszewski MJ, Nadolny K., Szarpak Ł. Risk of selfcontamination among healthcare workers in the COVID-19 pandemic.. J. Emerg. Med. 2020. 10.1016/j.ajem.2020.09.055.

29. Borkowska MJ, Smereka J, Safiejko K, Nadolny, Maslanka M, Filipiak KJ, Jaguszewski MJ, Szarpak Ł. Out-of-hospital cardiac arrest treated by emergency medical service teams during COVID-19 pandemic: A retrospective cohort study. Kardiol. Pol. 2020;78(12):1254-1261.

30. Budnik M, Nowak R, Fijałkowski M, Kochanowski J, Nargiełło E, Piątkowski R, Peller M, Kucharz J, Jaguszewski MJ, Gruchała M, Opolski G. Sex-dependent differences in clinical characteristics and in-hospital outcomes in patients with takotsubo syndrome. Pol. Arch. Med. Wewn. 2020 : vol. 130, nr 1, s. 25-30.

31. Cammann VL, Szawan KA, Stähli BE, Kato K, Budnik M, Wischnewsky M, Dreiding S, Levinson RA, Di Vece D, Gili S, Citro R, Bossone E, Neuhaus M, Franke J, Meder B, *Jaguszewski MJ, Noutsias M, Knorr M, Heiner S, D’Ascenzo F, Dichtl W, Burgdorf Ch, Kherad B, Tschöpe C, Sarcon A, Shinbane J, Rajan L, Michels G, Pfister R, Cuneo A, Jacobshagen C, Karakas M, Koenig W, Pott A, Meyer P, Roffi M, Banning A, Wolfrum M, Cuculi F, Kobza R, Fischer TA, Vasankari T, Airaksinen KEJ, Napp LC, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Chan C, Bridgman P, Beug D, Delmas C, Lairez O, Gilyarova E, Shilova A, Gilyarov M, El-Battrawy I, Akin I, Poledniková K, Toušek P, Winchester DE, Galuszka J, Ukena C, Poglajen G, Carrilho-Ferreira P, Hauck C, Paolini C, Bilato C, Kobayashi Y, Shoji T., Ishibashi I, Takahara M, Himi T, Din J, AlShammari A, Prasad A, Rihal CS, Liu K, Schulze C, Bianco M, Jörg L, Rickl H, Pestana G, Nguyen TH, Böhm M. Maier LS, Pinto FJ, Widimský P, Felix SB, Braun-Dullaeus RC, Rottbauer W, Hasenfuß G, Pieske BM, Schunkert H. Borggrefe M, Thiele H, Bauersachs J, Katus HA, Horowitz JD, Di Mario C, Münzel T, Crea F, Bax JJ, Lüscher TF, Ruschitzka F, Ghadri JR, Opolski G, Templin C. Age-Related Variations in Takotsubo Syndrome. J. Am. Coll. Cardiol . 2020; 75(16):1869-1877.

32. Carlos C, Johnson TW, Sigmund S, Buszman PP, Poerner TC, Francesco L, Borja I, Yongcheol K, Mischke K, Jaguszewski MJ, Gutiérrez-Chico JL. ISCHEMIA trial: the longawaited evidence to confirm our prejudices. Cardiol. J. 2020 : vol. 27, nr 4, s. 336-341.

33. Ciurzyński M, Domienik-Karłowicz J, Jaguszewski MJ, Pruszczyk P. COVID-19 and its implication for venous thromboembolism. Cardiol. J. 2020 : vol. 27, nr 5, s. 481-484.

34. D’Ascenzo F, Gili S, Bertaina M, Iannaccone M, Cammann VL, Di Vece D, Kato K, Saglietto A, Szawan KA, Frangieh AH, Boffini B, Annaratone M, Sarcon A, Levinson RA, Franke J, Napp C. Jaguszewski MJ, Noutsias M, Münzel T, Knorr M, Heiner S, Katus HA, Burgdorf C, Schunkert H, Thiele H, Bauersachs J, Tschöpe C, Pieske BM, Rajan B, Michels G, Pfister R, Cuneo A, Jacobshagen C, Hasenfuß G, Karakas M, Koenig W, Rottbauer W, Said SM, Braun-Dullaeus RC, Banning A, Cuculi F, Kobza R, Fischer TA, Vasankari T, Airaksinen KJE, Opolski G, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Crea F, Dichtl W, Franz WF, Empen K, Felix SB, Delmas C, Lairez O, El-Battrawy I, Akin I, Borggrefe M, Horowitz JD, Kozel M, Tousek P, Widimský P, Gilyarova E, Shilova A, Gilyarov M, Biondi-Zoccai G, Winchester DE, Ukena C, Neuhaus M, Bax JJ, Prasad A, Di Mario C, Böhm M, Gasparini M, Ruschitzka F, Bossone E, Citro R, Rinaldi M, De Ferrari GM, Lüscher T, Ghadri JR, Templin C. Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry. Eur. J. Heart Fail. 2020; 22(2):330-337.

35. Ding KJ, Cammann VL, Szawan KA, Stähli BE, Wischnewsky M, Di Vece D, Citro R, Jaguszewski MJ, Seifert B, Sarcon A, Knorr M, Heiner S, Gili S, D’Ascenzo F, Neuhaus M, Napp LC, Franke J, Noutsias M, Burgdorf C, Koenig W, Kherad B, Rajan L, Michels G, Pfister R, Cuneo A, Jacobshagen C, Karakas M, Pott A, Meyer P, Arroja JD, Banning A, Cuculi F, Kobza R, Fischer TA, Vasankari T, Airaksinen KEJ, Paolini C, Bilato C, Carrilho-Ferreira P, Opolski G, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, GaliutoL, Dichtl W, Chan C, Bridgman P, Delmas C, Lairez O, El-Battrawy I, Akin I, Gilyarova E, Shilova A, Gilyarov M, Kozel M, Tousek P, Widimský P, Winchester DE, Galuszka J, Ukena C, Horowitz JD, Di MC, Prasad A, Rihal CS, Pinto FJ, Crea F, Borggrefe M, Braun-Dullaeus RC, Rottbauer W, Bauersachs J, Katus HA, Hasenfuβ G, Tschöpe C, Pieske BM, Thiele H, Schunkert H, Böhm M, Felix SB, Münzel T, Bax JJ, Lüscher TF, Ruschitzka F, Ghardi JR, Bossone E, Templin C. Intraventricular thrombus formation and embolism in Takotsubo syndrome : insights from the International Takotsubo Registry. Arterioscler. Thromb. Vasc. Biol. 2020 : vol. 40, nr 1, s. 279-287.

36. Domienik-Karłowicz J, Jaguszewski MJ, Kurzyna M. Direct oral anticoagulants in cancerassociated venous thromboembolism: It is high time for a change of therapeutic paradigm. Cardiol. J. 2020; 27(4):347-349.

37. Drozd A, Smereka J, Filipiak KJ, Jaguszewski MJ, Ładny JR, Bielski K, Nadolny J, Ruetzler K, Szarpak Ł. Intraosseous versus intravenous access while wearing personal protective equipment: a meta-analysis in the era of COVID-19. Kardiol. Pol. 2021. doi: 10.33963/KP.15741.

38. Dzieciatkowski T, Szarpak Ł, Filipiak KJ, Jaguszewski MJ, Ladny JR, Smereka. COVID-19 challenge for modern medicine. Cardiol. J. 2020;27(2):175-183.

39. Engel LC, Landmesser U, Abdelwahed YS, Jaguszewski MJ, Gigengack K, Wurster TH, Skurk C, Manes C, Schuster A, Noutsias M, Hamm B, Botnar RM, Makowski MR, Bigalke B. Comprehensive multimodality characterization of hemodynamically significant and nonsignificant coronary lesions using invasive and noninvasive measures. PLoS One 2020; 15(1):e0228292.

40. Gasecka A, Siwik D, Gajewska M, Jaguszewski MJ, Mazurek T, Filipiak KJ, Postuła M, Eyileten C. Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes. J. Clin. Med. 2020 : vol. 9, nr 9, art. ID 2807, s. 1-12.

41. Gąsecka A, Filipiak KJ, Jaguszewski MJ. Impaired microcirculation function in COVID-19 and implications for potential therapies Cardiol. J. 2020 : vol. 27, nr 5, s. 485-488.

42. Gąsecka A, Rogula S, Eyileten C, Postuła M, Jaguszewski MJ, Kochman J, Mazurek T, Nieuwland R. Filipiak KJ. Role of P2Y Receptors in Platelet Extracellular Vesicle Release. Int. J. Mol. Sci. 2020; 21(17):6065.

43. Hellmann M, Piotrowski J, Kaszubowski M, Dudziak M, Anisimowicz L. Invasive Assessment of the Myocardial Microcirculation during Beating Heart Coronary Artery Bypass Grafting. J Clin Med. 2020 Mar 1;9(3):663. doi: 10.3390/jcm9030663.

44. Huang QF, Aparicio LS, Thijs L, Wei FF, Melgarejo JD, Cheng YB, Sheng CS, Yang WY, Gilis-Malinowska N, Boggia J, Niiranen TJ, Wojciechowska W, Stolarz-Skrzypek K, Barochiner J, Ackermann D, Tikhonoff V, Ponte B, Pruijm M, Casiglia E, Narkiewicz K, Filipovský J, Czarnecka D, Kawecka-Jaszcz K, Jula AM, Bochud M, Vanassche T, Verhamme P, Struijker-Boudier HAJ, Wang JG, Zhang ZY, Li Y, Staessen JA; IDCARS (International Database of Central Arterial Properties for Risk Stratification) Investigators. Cardiovascular End Points and Mortality Are Not Closer Associated With Central Than Peripheral Pulsatile Blood Pressure Components. Hypertension. 2020 Aug;76(2):350-358. doi: 10.1161/HYPERTENSIONAHA.120.14787.

45. Ishag A, Szarpak L, Filipiak KJ, Smereka J, Dabrowski M, Ghavami S, Jaguszewski MJ. Interferon lambda with remdesivir as a potential treatment option in COVID-19. Disaster Emerg. Med. J. 2020 : vol. 5, nr 3, s. 174.

46. Jaguszewski MJ. Odrębność leczenia w kardiologii inwazyjnej. [W:] Koronawirus SARS-CoV-2: zagrożenie dla współczesnego świata / red. nauk. T. Dziewiątkowski, K.J. Filipiak. Warszawa: PZWL Wydawnictwo Lekarskie, 2021. S. 144-149.

47. Jaguszewski MJ, Szarpak Ł, Filipiak KJ. Impact of COVID-19 pandemic on out-of-hospital cardiac arrest survival rate. Resuscitation 2020; 159:40-41.

48. Jurgiel J, Filipiak KJ, Szarpak Ł, Jaguszewski MJ, Smereka J, Dzieciątkowski T. Do pets protect their owners in the COVID-19 era? Med. Hypotheses 2020; 142:109831.

49. Kapłon-Cieślicka A, Kupczyńska K, Dobrowolski P, Michalski B, Jaguszewski MJ, Banasiak W, Burchardt P, Chrzanowski Ł, Darocha S, Domienik-Karłowicz J, Drożdż J, Fijałkowski M, Filipiak K, Gruchała M, Jankowska EA, Jankowski P, Kasprzak JD, Kosmala W, Lipiec P, Mitkowski P, Mizia-Stec K, Szymański P, Tycińska A, Wańha W, Wybraniec M, Witkowski A, Ponikowski P. On the search for the right definition of heart failure with preserved ejection fraction. Cardiol. J. 2020 : vol. 27, nr 5, s. 449-468.

50. Kowalik MM, Trzonkowski P, Łasińska-Kowara M, Mital A, Smiatacz T, Jaguszewski MJ. COVID-19 : Toward a comprehensive understanding of the disease. Cardiol. J. 2020 : vol. 27, nr 2, s. 99-114.

51. Kubica J, Adamski P, Niezgoda P, Alexopoulos D, Badariene J, Budaj A, Buszko K, Dudek D, Fabiszak T, Gąsior M, Gil R, Gorog D, Grajek S, Gurbel P, Gruchała M, Jaguszewski MJ, James S, Jeong Y, Jilma B, Kasprzak JD, Kleinrok A, Kubica A, Kuliczkowski W, Legutko J, Lesiak M, Siller-Matula JM, Nadolny K, Pstrągowski K, Di Somma S, Specchia G, Stępińska J, Tantry Udaya S, Tycińska A, Verdoia M, Wojakowski W, Navarese EP. Prolonged antithrombotic therapy in patients after acute coronary syndrome: a critical appraisal of current European Society of Cardiology guidelines. Med. Res. J. 2020 : vol. 5, nr 3, s. 177-190. 52. Ludwin K., Filipiak KJ, Jaguszewski M., Pruc M., Paprocki M., Smereka J., Szarpak ., Dabrowski M., Czekajlo M. Place of prefilled syringes in COVID-19 patient based on current evidence. Am. J. Emerg. Med. 2021; 39:234-235.

52. Ludwin K, Filipiak KJ, Jaguszewski MJ, Pruc M, Paprocki M, Smereka J, Szarpak Ł, Dabrowski M, Czekajlo M. Systematic review and meta-analysis appraising efficacy and safety of adrenaline for adult cardiopulmonary resuscitation. Cardiol. J. 2020. doi: 10.5603/CJ.a2020.0133

53. Ludwin K, Safiejko K, Smereka J, Nadolny K, Cyran M, Yakubtsevich R, Jaguszewski MJ, Filipiak KJ, Szarpak Ł, Rodríguez-Núñez A Effect of amiodarone and lidocaine on shock-refractory cardiac arrest: a systematic review and meta-analysis. Kardiol. Pol. 2020 : t. 78, nr 10, s. 999-1007.

54. Ludwin K, Smereka J, Nadolny K, Ładny JR, Szarpak A, Fajfer Z, Jaguszewski MJ, Filipiak KJ, Szarpak Ł. Cardiopulmonary resuscitation in the prone position: a good option for patients with COVID-19. Anesth. Analg. 2020: vol. 131, nr 3, s. e172-e173.

55. Ludwin K, Szarpak L, Ruetzler K, Smereka J, Böttiger BW, Jaguszewski MJ, Filipiak KJ. Cardiopulmonary resuscitation in the prone position: a good option for patients with COVID-19. Anesth. Analg. 2020 : vol. 131, nr 3, s. e172-e173.

56. Łoś A, Hellmann M. Real-time microcirculation imaging during beating-heart coronary artery bypass grafting. Kardiol Pol. 2020 Aug 25;78(7-8):780-781. doi: 10.33963/KP.15322. Epub 2020 Apr 28.

57. Malysz M, Dabrowski M, Böttiger BW, Smereka J, Kulak K, Szarpak A, Jaguszewski MJ, Filipiak KJ, Ladny JR, Ruetzler K., Szarpak Ł. Resuscitation of the patient with suspected/confirmed COVID-19 when wearing personal protective equipment: A randomized multicenter crossover simulation trial. Cardiol. J. 2020; 27(5):497-506.

58. Malysz M, Jaguszewski MJ, Szarpak L, Telecka-Gadek D, Bielski K, Dabrowska A, Smereka J, Filipiak KJ Comparison of different chest compression positions for use while wearing CBRN-PPE: a randomized crossover simulation trial. Disaster Emerg. Med. J. 2020: vol. 5, nr 3, s. 127-133.

59. Małysz M, Smereka J, Jaguszewski MJ, Dąbrowski M, Nadolny K, Ruetzler K, Ładny JR, Sterliński M, Filipiak KJ, Szarpak Ł. An optimal chest compression technique using personal protective equipment during resuscitation in the COVID-19 pandemic: a randomized crossover simulation study. Kardiol. Pol. 2020; 78(12):1254-1261.

60. Merks P, Drozd M, Świeczkowski D, Białoszewski A, Fehir Sola K, Harezlak T, Chmielewska-Ignatowicz T, Jaguszewski MJ. A comparison of patient attitudes towards community pharmacies in Poland and in England. Acta Pol. Pharm. – Drug Res. 2020 : vol. 77, nr 5, s. 805-813

61. Merks P, Jakubowska M, Drelich E, Świeczkowski D, Bogusz J, Bilmin K, Fehir SK, May A, Majchrowska A, Koziol M, Pawlikowski J, Jaguszewski MJ, Vaillancourt R. The legal extension of the role of pharmacists in light of the COVID-19 global pandemic. Res. Soc. Adm. Pharm. 2021 : vol. 17, nr 1, s. 1807-1812.

62. Merks P., Religioni U., Arciszewska K., Pankiewicz W., Jaguszewski M., Vaillancourt R. “Usability testing and satisfaction of “The Patient Access: A mobile health application for patients with venous thromboembolic disease. A pilot study. Cardiol. J. 2020. doi: 10.5603/CJ.a2020.0107.

63. Merks P, Świeczkowski D, Zerhau M, Gawronska A, Kowalczuk A, Gajewski K, Däinghaus R, Jaguszewski MJ, Brindley D. Pilot implementation of falsified medicines directive in hospital pharmacy to develop best practices for medicine decommissioning process. Pharmacy 2020 : vol. 8, nr 1, art. ID 34, s. 1-6.

64. Mickiewicz A, Futema M, Ćwiklińska A, Kuchta A, Jankowski M, Kaszubowski M, Chmara M, Wasąg B, Fijałkowski M, Jaguszewski MJ, Higher responsiveness to rosuvastatin in polygenic versus monogenic hypercholesterolemia: a propensity score analysis. Life (Basel) 2020 : vol. 10, nr 5, art ID 73, s. 1-14.

65. Napp LC, Cammann VL, Jaguszewski MJ, Szawan KA, Wischnewsky M, Gili S, Knorr M, Heiner S, Citro R, Bossone E, D’Ascenzo F, Neuhaus M, Franke J, Sorici-Barb I, Noutsias M, Burgdorf C, Koenig W, Kherad B, Sarcon A, Rajan L, Michels G, Pfister R, Cuneo A, Jacobshagen C, Karakas M, Pott A, Meyer P, Arroja JD, Banning A, Cuculi F, Kobza R, Fischer TA, Vasankari T, Airaksinen KEJ, Hauck C, Paolini C, Bilato C, Imori Y, Kato K, Kobayashi Y, Opolski G, Budnik M, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Dichtl W, Chan C, Bridgman P, Beug D, Delmas C, Lairez O, El-Battrawy I, Akin I, Gilyarova E, Shilova A, Gilyarov M, Horowitz JD, Polednikova K, Tousek P, Widimský P, Winchester DE, Galuszka J, Ukena C, Poglajen G, Carrilho-Ferreira P, Di Mario C, Prasad A, Rihal CS, Schulze PC, Bianco M, Crea F, Borggrefe M, Maier LS, Pinto FJ, Braun-Dullaeus RC, Rottbauer W, Katus HA, Hasenfuß G, Tschöpe C, Pieske BM, Thiele H, Schunkert H, Böhm M, Felix SB, Münzel T, Bax JJ, Bauersachs J, Braunwald E, Lüscher TF, Ruschitzka F, Ghadri JR, Templin C. Coexistence and outcome of coronary artery disease in Takotsubo syndrome. Eur. Heart J. 2020 : vol. 41, nr 34, s. 3255-3267.

66. Pajkowski M, Chlebus K, Hellmann M. Microvascular endothelial dysfunction in a young patient with familial hypercholesterolemia. Pol Arch Intern Med. 2020 Aug 27;130(7-8):679-680. doi: 10.20452/pamw.15411.

67. Piotrowski J, Anisimowicz L, Hellmann M. Laser Doppler flowmetry to assess myocardial microcirculation. Cardiol J. 2020 Feb 27. doi: 10.5603/CJ.a2020.0025.

68. Pruc M, Smereka J, Dzieciatkowski T, Jaguszewski MJ, Filipiak KJ, Szarpak Ł. Kawasaki disease shock syndrome or toxic shock syndrome in children and the relationship with COVID-19. Med Hypotheses. 2020; 144:109986.

69. Robak O, Dudek M, Ladny JR, Szarpak L, Gilis-Malinowska N, Frass M. Cardiac tamponade as a cause of COVID-19. Cardiol J. 2020;27(6):900-901. doi: 10.5603/CJ.2020.0175.

70. Safiejko K, Smereka J, Filipiak K, Szarpak A, Dabrowski M, Ladny JR, Jaguszewski MJ, Szarpak Ł. Effectiveness and safety of hypotension fluid resuscitation in traumatic hemorrhagic shock: a systematic review and meta-analysis of randomized controlled trials. Cardiol. J. 2020. doi: 10.5603/CJ.a2020.0096.

71. Safiejko K, Smereka J, Pruc M, Ladny JR, Jaguszewski MJ, Filipiak KJ, Yakubtsevich R, Szarpak Ł. Efficacy and safety of hypertonic saline solutions fluid resuscitation on hypovolemic shock: A systematic review and meta-analysis of randomized controlled trials. Cardiol. J . 2020. doi: 10.5603/CJ.a2020.0134.

72. Smereka J, Puslecki M, Ruetzler K, Filipiak KJ, Jaguszewski MJ, Ladny JR, Szarpak L. Extracorporeal membrane oxygenation in COVID-19. Cardiol. J. 2020 : vol. 27, nr 2, s. 216-217.

73. Smereka J, Ruetzler K, Szarpak L, Filipiak KJ, Jaguszewski MJ, Role of mask/respirator protection against SARS-CoV-2. Anesth. Analg. 2020 : vol. 131, nr 1, s. e33-e34.

74. Smereka J, Szarpak Ł, Filipiak KJ, Jaguszewski MJ, Ladny JR. Which intravascular access should we use in patients with suspected/confirmed COVID-19? Resuscitation 2020;151:8-9.

75. Stańska A, Fijałkowska J, Targoński R, Fijałkowski M, Jaguszewski MJ, Rogowski J, Szurowska E, Jagielak D. Transcatheter aortic valve implantation through a transcarotid approach and cerebral injury. Kardiol. Pol. 2020 : t. 78, nr 7-8, s. 756-758.

76. Szarpak L, Filipiak KJ, Mosteller L, Jaguszewski MJ, Smereka J, Ruetzler K, Sanchit A, Ladny JR. Survival, neurological and safety outcomes after out of hospital cardiac arrests treated by using prehospital therapeutic hypothermia: A systematic review and meta-analysis. Am. J. Emerg. Med. 2020; 10.1016/j.ajem.2020.02.019.

77. Szarpak L, Ruetzler K, Dabrowski M, Nadolny K, Ladny JR, Smereka J, Jaguszewski MJ, Filipiak KJ. Dilemmas in resuscitation of COVID-19 patients based on current evidence. Cardiol. J. 2020 : vol. 27, nr 3, s. 327-328.

78. Szarpak L, Ruetzler K, Safiejko K, Hampel M, Pruc M, Kanczuga-Koda L, Filipiak KJ, Jaguszewski MJ. Lactate dehydrogenase level as a COVID-19 severity marker. Am. J. Emerg. Med. 2020; doi: 10.1016/j.ajem.2020.11.025.

79. Szarpak L, Smereka J, Filipiak KJ, Ladny JR, Jaguszewski MJ. Cloth masks versus medical masks for COVID-19 protection. Cardiol. J. 2020 : vol. 27, nr 2, s. 218-219.

80. Szarpak Ł, Dzieciątkowski T, Jaguszewski MJ. Is remdesivir important in clinical practice as a treatment against COVID-19? A study based on meta-analysis data. Pol. Arch. Intern. Med. 2020. DOI: 10.20452/pamw.15686.

81. Szarpak Ł, Filipiak KJ, Gasecka A, Pruc M, Drozd A, Jaguszewski MJ. Correlation between takotsubo cardiomyopathy and SARS-CoV-2 infection. Med Hypotheses. 2020; 146:110454.

82. Szarpak Ł, Nowak B, Kosior D, Zaczynski A, Filipiak, KJ, Jaguszewski MJ. Cytokines as a predictor of COVID-19 severity: evidence from meta-analysis. Pol. Arch. Intern. Med. 2020. DOI: 10.20452/pamw.15685.

83. Szarpak Ł, Zaczynski A, Kosior D, Bialka S, Ladny JR, Gilis-Malinowska N, Smereka J, Kanczuga-Koda L, Gasecka A, Filipiak KJ, Jaguszewski MJ. Evidence of diagnostic value of ferritin in patients with COVID-19. Cardiol. J. 2020. doi: 10.5603/CJ.a2020.0171

84. Świeczkowski D, Zdanowski S, Merks P, Szarpak Ł, Vaillancourt R, Jaguszewski MJ. The plague of unexpected drug recalls and the pandemic of falsified medications in cardiovascular medicine as a threat to patient safety and global public health: A brief review. Cardiol. J. 2020. doi: 10.5603/CJ.a2020.0168

85. Świeczkowski D, Merks P, Jaguszewski MJ. The safe use of drugs on the example of qualitative analysis of opinions of Internet users about drugs containing the recalled valsartan – an exploratory study. J. Health Policy Outcomes Res. 2020, nr 1, s. 1-9.

86. Narożny A, Zdanowski S, Świeczkowski D, Jaguszewski MJ, Krysiński J, Merks P. Ocena poziomu satysfakcji pacjentów z etykietopiktogramów w aptece pilotażowej. Farm. Pol. 2020 : vol. 76, nr 4, s. 185-194.

87. Wańha W, Mielczarek M, Gilis-Malinowska N, Roleder T, Milewski M, Ładziński S, Ciećwierz D, Gąsior P, Pawłowski T, Januszek R, Kowalówka A, Kolodziejczak M, Bartuś S, Gruchała M, Smolka G, Navarese EP, Dudek D, Ochała A, Kedhi E, Jaguszewski MJ, Wojakowski W. Safety and Efficacy of Embolic Protection Devices in Saphenous Vein Graft Interventions: A Propensity Score Analysis-Multicenter SVG PCI PROTECTA Study. J. Clin. Med. 2020; 9(4):1198.

88. Wilkowski M, Lewicki Ł, Olszewski R, Priebe A, Jaguszewski MJ, Szołkiewicz M. First-inhuman radiofrequency ablation of ventricular tachycardia performed through an Atrial Flow Regulator device. Cardiol. J. 2020. doi: 10.5603/CJ.a2020.0172.

89. Wozniak-Mielczarek L, Sabiniewicz R, Nowak R, Gilis-Malinowska N, Osowicka M, Mielczarek M. New Screening Tool for Aortic Root Dilation in Children with Marfan Syndrome and Marfan-Like Disorders. Pediatr Cardiol. 2020 Mar;41(3):632-641. doi: 10.1007/s00246-02002307-0. Epub 2020 Jan 31.

90. Ćwiklińska A, Wieczorek E, Gliwińska A, Marcinkowska M, Czaplińska M, Mickiewicz A, Kuchta A, Kortas-Stempak B, Gruchała M, Dębska-Ślizień A, Król E, Jankowski M. Non-HDL-C/TG ratio indicates significant underestimation of calculated low-density lipoprotein cholesterol (LDL-C) better than TG level: a study on the reliability of mathematical formulas used for LDL-C estimation. Clin Chem Lab Med. 2020 Dec 24;59(5):857-867. doi: 10.1515/cclm-2020-1366. PMID: 33554544.

91. Hennig M, Brandt-Varma A, Wołoszyn-Durkiewicz A, Bautembach-Minkowska J, Buraczewska M, Świętoń D, Mickiewicz A, Rynkiewicz A, Gruchała M, Limon J, Wasąg B, Chmara M, Walczak M, Myśliwiec M. Monitoring the Effects of Hypolipidemic Treatment in Children with Familial Hypercholesterolemia in Poland. Life (Basel). 2020 Nov 4;10(11):270. doi: 10.3390/life10110270. PMID: 33158089; PMCID: PMC7694222.

92. Mickiewicz A, Kreft E, Kuchta A, Wieczorek E, Marlęga J, Ćwiklińska A, Paprzycka M, Gruchała M, Fijałkowski M, Jankowski M. The Impact of Lipoprotein Apheresis on Oxidative Stress Biomarkers and High-Density Lipoprotein Subfractions. Oxid Med Cell Longev. 2020 Aug 5;2020:9709542. doi: 10.1155/2020/9709542. PMID: 32832012; PMCID: PMC7428943.

93. Kanikowska D, Korybalska K, Mickiewicz A, Rutkowski R, Kuchta A, Sato M, Kreft E, Fijałkowski M, Gruchała M, Jankowski M, Bręborowicz A, Witowski J. Flaxseed (Linum Usitatissimum L.) Supplementation in Patients Undergoing Lipoprotein Apheresis for Severe Hyperlipidemia-A Pilot Study. Nutrients. 2020 Apr 18;12(4):1137. doi: 10.3390/nu12041137. PMID: 32325781; PMCID: PMC7231079.


CONTACT